04:41 PM EST, 11/11/2025 (MT Newswires) -- Profound Medical ( PROF ) was last seen up 2% in after-hours Nasdaq trade after the company on Tuesday said it sealed a deal with a Saudi Arabian company to distribute Tulsa-Pro and Sonnaleve.

Tulsa-Pro, which is designed specifically for the treatment of prostate disease, allows physicians to remove diseased tissue without any incisions and in out-patient settings.

Sonalleve, which is offered primarily as a one-time capital sale, is gaining increasing commercial interest, particularly outside of the U.S. Sonalleve uses the same imaging and technology as Tulsa-Pro, and combines that with targeted ultrasound to treat disease, a statement said. There are currently 10 Sonalleve devices operational in parts of Europe, China and Southeast Asia.

U.S. commercialization of Tulsa-Pro, remains the top priority for Profound's direct sales team. The company said Mondayit regained exclusive distribution rights for TulsaA-Proin Canada from Knight Therapeutics (GUD.TO).

Profound shares were last seen up US$0.13 to US$6.50 after hours. They closed up $0.68, or 8%, to $0.95 on the Toronto Stock Exchange.